NEUROCRINE BIOSCIENCES INC
NBIXNasdaq
$170.88
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +28.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$17.7B
Enterprise Value
$16.4B
P/E
26.3
P/S
5.7
P/B
5.2
EV/EBITDA
20.1
PEG
0.6
FCF Yield
4.7%
Dividend Yield
—
Revenue (TTM)
$3.1B
Net Income (TTM)
$668.6M
Free Cash Flow (TTM)
$831.3M
Gross Margin
—
Operating Margin
25.4%
Net Margin
21.6%
ROE
19.6%
ROIC
26.9%
Debt / Equity
—
Net Cash
$1.3B
Return 1Y
+27.4%
Company profile
Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.
- CEO
- Kevin C. Gorman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,200
- Headquarters
- California
- Website
- neurocrine.com
Management & directors
- Delaet IngridChief Regulatory Officer
- Lippoldt DarinChief Legal Officer
- Onyia JudeChief Scientific Officer
- Cooke JulieChief Human Resources Officer
- Keswani SanjayChief Medical Officer
- Boyer David W.Chief Corp. Affairs Officer
- Abernethy MattChief Financial Officer
- Benevich EricChief Commercial Officer
- Gano KyleChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
NBIX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$814.5M↑ +42.2%
Diluted EPS$1.91↑ +2287.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.5B | $1.9B | $2.4B | $2.9B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| Net income | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| Diluted EPS | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| Operating cash flow | $228.5M | $256.5M | $339.4M | $389.9M | $595.4M | $782.7M |
| Free cash flow | $217.6M | $233.1M | $322.9M | $361.6M | $557.2M | $748.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Net margin | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $590.2M | $622.1M | $627.7M | $572.6M | $687.5M | $794.9M | $805.5M | $814.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $145.4M | $183.8M | $142.0M | $23.6M | $145.6M | $239.0M | $210.9M | $193.4M |
| Net income | $65.0M | $129.8M | $103.1M | $7.9M | $107.5M | $209.5M | $153.7M | $197.9M |
| Diluted EPS | $0.63 | $1.24 | $1.00 | $0.08 | $1.06 | $2.04 | $1.49 | $1.91 |
| Operating cash flow | $64.6M | $158.0M | $242.5M | $64.8M | $102.0M | $227.5M | $388.4M | $145.8M |
| Free cash flow | $53.0M | $149.9M | $235.2M | $54.1M | $89.5M | $214.3M | $386.0M | $136.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 24.6% | 29.5% | 22.6% | 4.1% | 21.2% | 30.1% | 26.2% | 23.7% |
| Net margin | 11.0% | 20.9% | 16.4% | 1.4% | 15.6% | 26.4% | 19.1% | 24.3% |
Company news
Jul 16, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Delaet Ingrid· Chief Regulatory Officer | Sale | 4,367 | $181.02 | $790,514.34 | filing |
| 2026-07-10 | Delaet Ingrid· Chief Regulatory Officer | Option exercise | 4,367 | $106.02 | $462,989.34 | filing |
| 2026-07-09 | Lippoldt Darin· Chief Legal Officer | Sale | 10,000 | $179.60 | $1.8M | filing |
| 2026-07-09 | Delaet Ingrid· Chief Regulatory Officer | Sale | 8,433 | $178.72 | $1.5M | filing |
| 2026-07-09 | Delaet Ingrid· Chief Regulatory Officer | Option exercise | 8,433 | $103.52 | $872,984.16 | filing |
| 2026-07-09 | Lippoldt Darin· Chief Legal Officer | Option exercise | 10,000 | $81.49 | $814,900.00 | filing |
| 2026-07-08 | Delaet Ingrid· Chief Regulatory Officer | Sale | 2,737 | $178.54 | $488,672.19 | filing |
| 2026-07-08 | Delaet Ingrid· Chief Regulatory Officer | Option exercise | 2,737 | $103.52 | $283,334.24 | filing |
| 2026-07-07 | Delaet Ingrid· Chief Regulatory Officer | Sale | 3,401 | $178.57 | $607,305.01 | filing |
| 2026-07-07 | Delaet Ingrid· Chief Regulatory Officer | Option exercise | 3,401 | $103.52 | $352,071.52 | filing |
| 2026-06-29 | Lippoldt Darin· Chief Legal Officer | Sale | 8,110 | $170.03 | $1.4M | filing |
| 2026-06-29 | Lippoldt Darin· Chief Legal Officer | Option exercise | 8,110 | $81.49 | $660,883.90 | filing |
| 2026-06-29 | Lippoldt Darin· Chief Legal Officer | Sale | 1,690 | $170.81 | $288,676.34 | filing |
| 2026-06-29 | Lippoldt Darin· Chief Legal Officer | Option exercise | 1,690 | $81.49 | $137,718.10 | filing |
| 2026-06-26 | Lippoldt Darin· Chief Legal Officer | Sale | 200 | $169.57 | $33,913.00 | filing |
| 2026-06-26 | Lippoldt Darin· Chief Legal Officer | Option exercise | 200 | $81.49 | $16,298.00 | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Sale | 7,883 | $163.81 | $1.3M | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Sale | 6,896 | $165.79 | $1.1M | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Sale | 5,829 | $166.56 | $970,859.00 | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Option exercise | 15,000 | $53.64 | $804,600.00 | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Option exercise | 10,000 | $79.79 | $797,900.00 | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Sale | 2,549 | $164.44 | $419,156.03 | filing |
| 2026-06-05 | SHERWIN STEPHEN A | Sale | 1,843 | $167.31 | $308,357.49 | filing |
| 2026-06-05 | Onyia Jude· Chief Scientific Officer | Gift | 2,441 | $0.00 | $0.00 | filing |
| 2026-06-04 | Norwalk Leslie V | Sale | 1,250 | $168.06 | $210,071.63 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.